PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsPolytetrafluoroethylene
Polytetrafluoroethylene
Skin Exposure Reduction Paste Against Chemical Warfare Agents (polytetrafluoroethylene) is a small molecule pharmaceutical. Polytetrafluoroethylene was first approved as Skin exposure reduction paste against chemical warfare agents on 2000-02-17.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
122 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HerniaD006547HP_0100790K40-K46——1247
Tooth lossD016388———11135
IschemiaD007511EFO_0000556————112
Chronic limb-threatening ischemiaD000089802—————112
Peripheral catheterizationD002406—————112
Inguinal herniaD006552HP_0000023K40———112
Acute coronary syndromeD054058EFO_0005672————1—1
SyndromeD013577—————1—1
DehydrationD003681—E86.0———1—1
Ventral herniaD006555EFO_1001866K43———1—1
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Alveolar bone lossD016301———21—35
Hiatal herniaD006551EFO_0007216K44——1—12
Peri-implantitisD057873EFO_1001390———1—12
Peripheral nerve injuriesD059348———11——1
Pyloric stenosisD011707—K31.1——1——1
Gastric outlet obstructionD017219EFO_1000947———1——1
Periodontal diseasesD010510—K05.6——1——1
HyperemiaD006940EFO_0003822——11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920HP_0000819E08-E1311——45
FibrosisD005355———1——34
Chronic kidney failureD007676EFO_0003884N18.912——24
Renal insufficiencyD051437HP_0000083N1911——34
Liver cirrhosisD008103EFO_0001422K74.0—1——23
Tissue adhesionsD000267———1——12
PsoriasisD011565EFO_0000676L40—2———2
ProctitisD011349EFO_0005628K62.89—1———1
TelangiectasisD013684———1———1
Radiation injuriesD011832———1———1
Show 8 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Dental implantsD015921——1———23
Soft tissue injuriesD017695——1———12
Urinary bladder neoplasmsD001749—C671————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InflammationD007249MP_0001845—————44
Type 1 diabetes mellitusD003922EFO_0001359E10————33
HypertensionD006973EFO_0000537I10————33
Heart failureD006333HP_0001635I50————33
HemorrhageD006470MP_0001914R58————33
Tooth extractionD014081——————33
Tissue preservationD014021——————33
ProlapseD011391——————33
Peripheral arterial diseaseD058729EFO_0004265—————33
Peripheral vascular diseasesD016491EFO_0003875I73.9————33
Show 102 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePolytetrafluoroethylene
INNpolitef
Description
Polytetrafluoroethylene (PTFE) is a synthetic fluoropolymer of tetrafluoroethylene. It belongs to the per- and polyfluoroalkyl substances (PFAS)) and has numerous applications. The commonly known brand name of PTFE-based composition is Teflon by Chemours, a spin-off from DuPont, which originally discovered the compound in 1938.
Classification
Small molecule
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID9002-84-0
RxCUI—
ChEMBL IDCHEMBL1201480
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDE1NC1JVS3O (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 29,178 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use